Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Tuebingen – page 11

612 clinical trials in Tuebingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Tuebingen at a glance
612
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

612 trials in Tuebingen

Open in trial search

Study on Pembrolizumab and Drug Combination for Patients with Recurrent Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitaet Des Saarlandes

Evaluation of remibrutinib (LOU064) effectiveness and safety in adult patients with chronic urticaria: A 12-week placebo-controlled study

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on Long-term Safety and Efficacy of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Breast cancer

Recruiting

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Study on MB-CART2219.1 for Adults and Children with Relapsed or Refractory B-cell Malignancies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:MB-CART2219.1
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study on the Effectiveness and Safety of Sepofarsen for Patients with Leber Congenital Amaurosis Due to a Specific Genetic Mutation

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepofarsen
  • Sponsor:Laboratoires Thea

Study on the Effectiveness and Safety of GAL-101 Eye Drops for Patients with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:SODIUM (R)-2-(2-AMINO-3-(1H-INDOL-3- YL)PROPANAMIDO)-2-METHYLPROPANOATE-PROPAN-2-OL
  • Sponsor:Galimedix Therapeutics Inc.

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Heidelberg University

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Tuebingen

What the registry says about research in the country

01 Neurology and Stroke Care

In Tübingen, clinical research in nervous system diseases focuses on improving outcomes for people with acute ischemic stroke, Parkinson disease, and multiple system atrophy. These studies are testing new treatment strategies and better ways to restore function after neurological injury or slow disease progression.

  • Acute ischemic stroke with incomplete reperfusion
  • Stroke in patients with recent direct oral anticoagulant use
  • Parkinson disease and multiple system atrophy
  • New approaches to treatment effectiveness and recovery

The research also includes imaging and diagnostic work, reflecting a broader effort to refine how brain disorders are detected and managed.

02 Oncology and Hematology

Clinical trials in neoplasms and hemic and lymphatic diseases are exploring targeted and immune-based treatments for a wide range of cancers, including renal cell carcinoma, follicular lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The aim is to improve survival, control relapse, and expand options for hard-to-treat disease.

  • Metastatic renal cell carcinoma
  • Relapsed and refractory follicular lymphoma
  • Chronic lymphocytic leukemia and Philadelphia chromosome-positive B-ALL
  • Evaluation of combination therapies and immune-based cancer control

Research in this area also covers solid tumors such as glioblastoma, colorectal cancer, melanoma, sarcoma, and neuroblastoma.

03 Pain, Anesthesia, and Critical Care

Studies in anesthesia and analgesia and pathological conditions are addressing chronic and acute pain, sedation, and treatment support for severely ill patients. Several trials are evaluating whether new approaches can ease persistent pain while improving safety in complex hospital settings.

  • Chronic back pain and neuropathic pain syndromes
  • Critical illness with mechanical ventilation and intensive care support
  • Older critically ill patients receiving early sedation strategies
  • Testing symptom relief and treatment tolerability

This area highlights both comfort-focused care and the search for better outcomes in intensive care medicine.

04 Cardiovascular and Thromboembolic Research

Research in cardiovascular diseases is examining how to reduce stroke, bleeding, and other vascular complications in high-risk patients. Trials in the city are especially focused on prevention after heart procedures and in people with complex clotting or bleeding histories.

  • Aortic valve stenosis and care after transcatheter valve implantation
  • High-risk atrial fibrillation with prior intracranial hemorrhage
  • Risk reduction for stroke and systemic embolism
  • Personalized antithrombotic treatment strategies

These studies aim to make anticoagulation and antiplatelet treatment safer and more precise.

05 Respiratory and Neonatal Medicine

Trials in respiratory tract diseases are centered on premature infants and lung development, with an emphasis on early support that may improve long-term breathing outcomes. The research also extends to critically ill newborns needing specialized care shortly after birth.

  • Respiratory distress syndrome in preterm infants
  • Prophylactic surfactant use in very premature babies
  • Long-term lung function in childhood
  • Improving neonatal respiratory support

These studies reflect a strong interest in protecting fragile infants during the earliest stages of life.

06 Eye and Skin Disease Studies

Clinical research in eye diseases and skin and connective tissue diseases is evaluating treatments for progressive vision loss and persistent inflammatory skin conditions. The goal is to slow disease-related damage and improve day-to-day quality of life.

  • Non-foveal geographic atrophy in age-related macular degeneration
  • Prurigo nodularis
  • Basal cell carcinoma and cutaneous squamous cell carcinoma
  • Testing new therapies for lesion control and symptom relief

There is also interest in treatment approaches for difficult-to-manage skin cancers and chronic itch.

07 Kidney, Urinary, and Prostate Cancer Research

Studies in male urogenital diseases are focusing on cancers of the kidney, urinary tract, and prostate. These trials are evaluating whether newer treatments can better control tumor growth and preserve organ function.

  • Metastatic renal cell carcinoma
  • Low-grade upper tract urothelial cancer
  • Metastatic hormone-sensitive prostate cancer
  • Improving cancer control and treatment effectiveness

Some work also looks at protecting renal function, especially in patients facing additional medical risks.

08 Pediatric Oncology

Research in pediatric cancer is addressing some of the most challenging childhood tumors, including high-risk neuroblastoma and childhood renal tumors. These studies are designed to improve response rates and long-term event-free survival in young patients.

  • High-risk neuroblastoma
  • Stage IV childhood renal tumor
  • Response after treatment for advanced disease
  • Testing intensified and combined treatment strategies

This area includes efforts to strengthen treatment for children with metastatic or relapsed disease.

09 Immune and Transplant-Related Diseases

Trials in immune system diseases are investigating ways to manage overactive immune responses and complications after transplantation. The main focus is on improving disease control while reducing treatment burden and side effects.

  • Chronic graft versus host disease
  • Therapies that modulate immune activity
  • Supportive care for immune-mediated complications
  • Evaluation of treatment benefit and tolerability

These studies are especially relevant for patients needing long-term immune regulation after intensive therapy.

10 Psychiatry, Psychology, and Pediatric Behavioral Health

In the field of mental disorders, investigators are exploring safer and more effective ways to support children and adolescents treated with antipsychotic medicines. The research also includes conditions such as autism spectrum disorder, showing a broad interest in developmental and behavioral health.

  • Medication monitoring for risperidone and aripiprazole
  • Weight gain and treatment tolerability in young patients
  • Autism spectrum disorder
  • Improving safety in long-term psychiatric care

These studies aim to make treatment more personalized for younger patients.

11 Diagnostic and Translational Imaging

Some trials in Tübingen concentrate on diagnosis and imaging tools, aiming to improve how disease processes are detected and monitored. This includes work in neurological and cancer-related settings where earlier or more precise identification could support better treatment decisions.

  • Diagnostic imaging for brain and movement disorders
  • Assessment of disease activity in cancer and neurology
  • Evaluating new tools for clinical detection
  • Supporting more accurate treatment planning

These studies help bridge laboratory research and practical patient care.

12 Specialized Therapeutic Techniques and Equipment

Research in therapeutics and related clinical techniques includes novel treatment approaches that combine device-based care, drug therapy, and procedure-guided interventions. The studies often target complex diseases where standard options are limited.

  • Stroke treatment and clot removal support
  • Image-guided and personalized treatment strategies
  • Procedure-based care in oncology and cardiovascular medicine
  • Testing whether new therapeutic combinations improve outcomes

This reflects a strong interest in practical innovations that can be integrated into routine care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.